BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zanolimumab: Phase III resumed

TenX resumed the second portion of an open-label, international Phase III trial to evaluate 14 mg/kg IV zanolimumab given weekly for 12 weeks in 70 patients. After...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >